SRPT News and Press, Sarepta Therapeutics Inc.

2024-06-26 10:06:00 ET When one player stumbles in a high-stakes competition, it's often to the glee of the other contenders. In mid-June, Pfizer 's (NYSE: PFE) gene-therapy candidate to treat Duchenne muscular dystrophy (DMD) didn't hit the mark in a late-stage clinical trial; it'd...

2024-06-26 09:10:26 ET More on Sarepta Therapeutics Sarepta Therapeutics: Pushing The Edge And Creating The Horizon Sarepta Therapeutics: Why Today's Rally On DMD Drug Label Expansion Won't Last Sarepta Therapeutics: Navigating Elevidys Upside Potential Trend...

2024-06-25 09:00:00 ET Summary Catalent stock rose 3% after Elevidys label expansion approval by the FDA. Sarepta's stock reached an all-time high after Elevidys label expansion approval. Several companies including PFE, CAPR, RGNX, SLDB, VRTX, have DMD gene-therapy product candid...

2024-06-22 12:46:00 ET The stock indexes were mixed this week, as investors and traders assessed a string of economic data, including U.S. PMI composite that ticked up unexpectedly in flash June print.... Read the full article on Seeking Alpha For further details see: Tr...

2024-06-22 06:47:18 ET Summary Sarepta Therapeutics excels in rare disease therapies using RNA, gene editing, and gene therapies, with significant revenue growth driven by ELEVIDYS gene therapy approval. Despite missing the primary endpoint, ELEVIDYS hit key secondary endpoints, l...

A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 3.2% to $126.57 on volume of 604,432,871 shares American Rebel Holdings Inc. (AREB) rose 152.5% to $0.76 on volume of 367,740,589 shares Sirius XM Holdings Inc. (SIRI) rose 1.0% to $2.93 on volume of 329...

2024-06-21 14:05:48 ET Summary Sarepta Therapeutics' gene therapy Elevidys has been granted label extension to treat Duchenne Muscular Dystrophy patients aged 4 and above. Sarepta Therapeutics stock price soars over 30% to >$160 following the news, on potential for profitabilit...

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is one of today's top gainers. The company's shares have moved 34.64% on the day to $166.22. Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies...

2024-06-21 10:15:03 ET Needham analyst issues BUY recommendation for SRPT on June 21, 2024 08:32AM ET. The previous analyst recommendation was Buy. SRPT was trading at $162.91 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...

2024-06-21 10:03:58 ET More on Catalent Catalent shareholders approve acquisition by Novo Holdings Catalent, Novo Nordisk receive FTC request for more information Seeking Alpha’s Quant Rating on Catalent Historical earnings data for Catalent Fi...